Abstract
Background: Behavioural medicine is characterised by findings for the effectiveness and efficacy of complex behaviour change interventions. Comparatively, scant attention has been paid to key intervention components or mechanisms of action. Evaluating relationships between process variables (fidelity) and intervention effects is central to addressing this imbalance. Accordingly, in the current study, we sought to explore the magnitude and direction of effect between fidelity predictors (dietitian adherence and competence) and intervention effects (patient nutritional status) during the intervention phase of a real-world, stepped-wedge evaluation of ‘EAT: Eating As Treatment’. Methods: The EAT clinical trial was conducted within five major Australian hospitals located in Queensland, Western Australia, Victoria and South Australia between 2013 and 2016. EAT is a dietitian-delivered health behaviour change intervention designed to reduce malnutrition in head and neck cance
· Co-design tools and processes for rapid, ongoing technical learning
· Conduct process documentation of PSI Nigeria’s design work.
· Facilitate and document regular After-Action Reviews to ensure structured, team-wide reflection and learning.
· Execute structured capture of insights, insight synthesis, and resulting decisions using tools co-developed with other PSI Global partners. This will be done collaboratively with PSI’s Sr. SRH Advisor – Implementation Science & Learning
· In collaboration with project, M&E, and marketing leads, develop and execute prototyping assessment protocols, including rubrics for assessment and standards/templates for documentation of prototypes, ensuring alignment with agreed-upon thresholds of evidence and methodological rigor.
· Rigorously document prototyping, including methods, prototype characteristics, and assessment results.
Health Equity Requires Understanding Diversity of Patient Plus Coordinated Inclusion Strategy
Share Article
Major health systems are recognizing that health equity is only feasible when comprehensive, coordinated initiatives link quality of care to a culture of inclusion. Dr. Maria Hernandez, founder of Impact4Health, has seen increasing concerns and demands for more engagement among clinicians and administrators to address unconscious bias, culturally effective care and involving community partners in healthcare.
Creating a culture of inclusion is a strategic choice when it comes to recruitment, training and designing patient services in healthcare systems.
Treating everyone the same assumes all patients have the same resources or live in the same conditions and that’s painfully not the case.
Article content
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
New drug helps COVID-19 patients breathe on their own
We apologize, but this video has failed to load.
Try refreshing your browser, or New antibody drug helps patients breathe; virus may insert genetic fragments into genetic code Back to video
When a new monoclonal antibody drug was added to treatments being given to hospitalized COVID-19 patients who were still breathing on their own, the drug – lenzilumab from Humanigen Inc – significantly improved their odds of not needing invasive mechanical ventilation, researchers found. The 540 patients in the randomized trial were already receiving a variety of standard treatments. Half of them also received lenzilumab via three intravenous infusions. In a paper posted on Wednesday on medRxiv ahead of peer review, the research team re